Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) said it is embarking on a potentially transformational year backed by a €2.89 million grant aimed at building on its research in the realm of longevity.
Central to its strategy is the advancement of GF-1002, a promising drug candidate for non-alcoholic steatohepatitis (NASH), now moving towards investigational new drug-enabling stages.
At the same time, it is interacting with the European Medicines Agency regarding a novel compound for Werner Syndrome, where sufferers show signs of aging in their 20s.
"While 2023 was a pivotal year, we're poised for an even stronger 2024, as we shift focus to scaling development of our lead drug candidate, GF-1002, and its potential benefits for NASH patients," said chief executive Eric Leire.
"With the support of our partners and the backing of new grants, we are poised to make meaningful advancements in the field of longevity."